Navigation Links
Agendia Receives €1.27 Million in Funding from the EU's Seventh Framework Programme
Date:7/21/2011

IRVINE, California and AMSTERDAM, July 21, 2011 /PRNewswire/ --


 

Agendia, a global innovator in molecular cancer diagnostics, announced today that, together with thought-leading collaborators in clinical centers and translational research groups, it has launched the RATHER (Rational Therapy for Breast Cancer) and COLTHERES (Colon Cancer and Therapeutics) consortiums. The partnerships will collectively receive nearly €12 million in funding from the European Union's 7th Framework Programme over a five-year term. Agendia, in particular, will receive €1.27 million for the development of new molecular diagnostics to help guide individualized treatment of cancer patients.

Both consortiums will be focused on gaining deeper insight into molecular subtypes of breast and colon cancer, and the development of biomarkers for use in predicting patients' individual responses to new targeted drugs. While RATHER seeks to improve treatment for triple negative and lobular breast cancer patients, COLTHERES is focused on response or resistance to targeted therapeutics in colon cancer. Both consortiums consist of clinical partners as well as leading translational research groups with a proven track record in developing companion diagnostics for cancer therapies. The objective of these partnerships is to define and perform biomarker-driven clinical trials to improve cancer therapy outcomes, with Agendia developing reliable and standardized biomarker tests.

Other members of the consortiums include the University College Dublin, the Netherlands Cancer Institute (NKI) Amsterdam, Institute Curie Paris, Malmö University Hospital Lund, Vall d'Hebron Barcelona, University of Cambridge, OncoMark Ltd Dublin, University of Leuven, Niguarda Ca' Granda Hospital Milano, IDIBELL Barcelona, Horizon Discovery UK, University of Liverpool, Swiss Institute of Bioinformatics and the University of Torino School of Medicine.

"We are pleased to participate in these EU funded projects and to work with these outstanding international experts in the fields of functional genomics, pharmacogenetics, bio-informatics and clinical oncology," said Prof. Dr. Rene Bernards, CSO of Agendia. "For Agendia, this is a great opportunity to develop new companion diagnostics together with a large group of scientists and physicians to address urgent clinical needs. The unique consortium structures will allow a rapid translation of results from research and discovery into a clinical setting that benefits patients."

About Agendia:

Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and who can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States. For more information, please visit http://www.agendia.com.

For more information on COLTHERES consortium go to http://www.coltheres.eu/. For more information on the RATHER Project go to http://www.ratherproject.com/.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
2. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
3. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
4. FDA Broadens Clearance for Agendias MammaPrint(R)
5. /C O R R E C T I O N -- Agendia B.V./
6. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
7. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
10. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
11. Agendia Launches TargetPrint(R) for Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):